These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37202753)

  • 1. Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.
    Cesari E; Ciucci A; Pieraccioli M; Caggiano C; Nero C; Bonvissuto D; Sillano F; Buttarelli M; Piermattei A; Loverro M; Camarda F; Greco V; De Bonis M; Minucci A; Gallo D; Urbani A; Vizzielli G; Scambia G; Sette C
    J Exp Clin Cancer Res; 2023 May; 42(1):126. PubMed ID: 37202753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma.
    Pitolli C; Marini A; Guerra M; Pieraccioli M; Marabitti V; Palluzzi F; Giacò L; Tamburrini G; Cecconi F; Nazio F; Sette C; Pagliarini V
    J Exp Clin Cancer Res; 2023 Aug; 42(1):214. PubMed ID: 37599362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.
    Zhang T; Kwiatkowski N; Olson CM; Dixon-Clarke SE; Abraham BJ; Greifenberg AK; Ficarro SB; Elkins JM; Liang Y; Hannett NM; Manz T; Hao M; Bartkowiak B; Greenleaf AL; Marto JA; Geyer M; Bullock AN; Young RA; Gray NS
    Nat Chem Biol; 2016 Oct; 12(10):876-84. PubMed ID: 27571479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer.
    Cheng L; Zhou S; Zhou S; Shi K; Cheng Y; Cai MC; Ye K; Lin L; Zhang Z; Jia C; Xiang H; Zang J; Zhang M; Yin X; Li Y; Di W; Zhuang G; Tan L
    Cancer Res; 2022 Oct; 82(19):3588-3602. PubMed ID: 35857807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.
    Wang C; Wang H; Lieftink C; du Chatinier A; Gao D; Jin G; Jin H; Beijersbergen RL; Qin W; Bernards R
    Gut; 2020 Apr; 69(4):727-736. PubMed ID: 31519701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells.
    Zhang G; Lan B; Zhang X; Lin M; Liu Y; Chen J; Guo F
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37164450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma.
    Jiang B; Jiang J; Kaltheuner IH; Iniguez AB; Anand K; Ferguson FM; Ficarro SB; Seong BKA; Greifenberg AK; Dust S; Kwiatkowski NP; Marto JA; Stegmaier K; Zhang T; Geyer M; Gray NS
    Eur J Med Chem; 2021 Oct; 221():113481. PubMed ID: 33945934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.
    Greenleaf AL
    Transcription; 2019 Apr; 10(2):91-110. PubMed ID: 30319007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13.
    Tien JC; Luo J; Chang Y; Zhang Y; Cheng Y; Wang X; Yang J; Mannan R; Mahapatra S; Shah P; Wang XM; Todd AJ; Eyunni S; Cheng C; Rebernick RJ; Xiao L; Bao Y; Neiswender J; Brough R; Pettitt SJ; Cao X; Miner SJ; Zhou L; Wu YM; Labanca E; Wang Y; Parolia A; Cieslik M; Robinson DR; Wang Z; Feng FY; Chou J; Lord CJ; Ding K; Chinnaiyan AM
    Cell Rep Med; 2024 Oct; 5(10):101758. PubMed ID: 39368479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.
    Zeng M; Kwiatkowski NP; Zhang T; Nabet B; Xu M; Liang Y; Quan C; Wang J; Hao M; Palakurthi S; Zhou S; Zeng Q; Kirschmeier PT; Meghani K; Leggett AL; Qi J; Shapiro GI; Liu JF; Matulonis UA; Lin CY; Konstantinopoulos PA; Gray NS
    Elife; 2018 Nov; 7():. PubMed ID: 30422115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer.
    Lei H; Wang Z; Jiang D; Liu F; Liu M; Lei X; Yang Y; He B; Yan M; Huang H; Liu Q; Pang J
    Cell Death Dis; 2021 Jul; 12(8):740. PubMed ID: 34315855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing.
    Liang K; Gao X; Gilmore JM; Florens L; Washburn MP; Smith E; Shilatifard A
    Mol Cell Biol; 2015 Mar; 35(6):928-38. PubMed ID: 25561469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development, validation, and evaluation of a deep learning model to screen cyclin-dependent kinase 12 inhibitors in cancers.
    Wen T; Wang J; Lu R; Tan S; Li P; Yao X; Liu H; Yi Z; Li L; Liu S; Gao P; Qian H; Xie G; Ma F
    Eur J Med Chem; 2023 Mar; 250():115199. PubMed ID: 36827953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors.
    van der Noord VE; van der Stel W; Louwerens G; Verhoeven D; Kuiken HJ; Lieftink C; Grandits M; Ecker GF; Beijersbergen RL; Bouwman P; Le Dévédec SE; van de Water B
    Breast Cancer Res; 2023 May; 25(1):51. PubMed ID: 37147730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The promise and current status of CDK12/13 inhibition for the treatment of cancer.
    Tadesse S; Duckett DR; Monastyrskyi A
    Future Med Chem; 2021 Jan; 13(2):117-141. PubMed ID: 33295810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.
    Blazek D; Kohoutek J; Bartholomeeusen K; Johansen E; Hulinkova P; Luo Z; Cimermancic P; Ule J; Peterlin BM
    Genes Dev; 2011 Oct; 25(20):2158-72. PubMed ID: 22012619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma.
    Geng M; Yang Y; Cao X; Dang L; Zhang T; Zhang L
    Biochem Biophys Res Commun; 2019 Dec; 520(3):544-550. PubMed ID: 31615655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
    Niu T; Li K; Jiang L; Zhou Z; Hong J; Chen X; Dong X; He Q; Cao J; Yang B; Zhu CL
    Eur J Med Chem; 2022 Jan; 228():114012. PubMed ID: 34864331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-grade serous ovarian carcinoma organoids as models of chromosomal instability.
    Vias M; Morrill Gavarró L; Sauer CM; Sanders DA; Piskorz AM; Couturier DL; Ballereau S; Hernando B; Schneider MP; Hall J; Correia-Martins F; Markowetz F; Macintyre G; Brenton JD
    Elife; 2023 May; 12():. PubMed ID: 37166279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
    Quereda V; Bayle S; Vena F; Frydman SM; Monastyrskyi A; Roush WR; Duckett DR
    Cancer Cell; 2019 Nov; 36(5):545-558.e7. PubMed ID: 31668947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.